Four adalimumabs compete in EU
Four separate biosimilar versions of AbbVie’s Humira (adalimumab) are competing for market share in the European Union (EU), after Amgen, Mylan, Samsung Bioepis and Sandoz all launched into European markets immediately after a key supplementary protection certificate (SPC) protecting the autoimmune treatment expired. Amgen, Mylan and Samsung Bioepis said their respective Amgevita, Hulio and Imraldi biosimilars had launched in markets across Europe, including in Italy for Amgen. A Sandoz spokesperson told Generics bulletin the company – which has received approval under the Hyrimoz, Halimatoz and Hefiya labels – had “launched and supplied” its adalimumab in Germany and the UK, while it had placed tender bids in the Netherlands and Ukraine.
You may also be interested in...
A year to the day since the launch of the first US rival to Humira, adalimumab biosimilars are still struggling to gain a significant foothold in the market. Generics Bulletin looks at the reasons why.
Sandoz has launched the high-concentration version of its Hyrimoz adalimumab biosimilar rival to Humira in Europe.
Sandoz has received a formal European approval for its high-concentration Hyrimoz biosimilar rival to Humira, setting the stage for it to enter a market that also includes versions from Alvotech/Stada and Celltrion.